Yahoo Finance

Sichuan Kelun-Biotech Biopharmaceutical has shown impressive growth, with revenue increasing by 24.7% over the past year and a forecasted annual revenue growth of 25.2%. Despite being unprofitable, the company is expected to become profitable in the next three years, aligning with its robust R&D investments. Significant progress in their sacituzumab tirumotecan (sac-TMT) trials for various cancers highlights innovation potential; recent Phase 3 results demonstrated a median progression-free survival of 5.6 months versus 2.7 months for standard treatments in TNBC patients.

• Click to explore a detailed breakdown of our findings in Sichuan Kelun-Biotech Biopharmaceutical's health report.

• Examine Sichuan Kelun-Biotech Biopharmaceutical's past performance report to understand how it has performed in the past.

Akeso

Simply Wall St Growth Rating: ★★★★★★

Overview: Akeso, Inc. is a biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of antibody drugs with a market cap of HK$48.31 billion.

Operations: The company generates revenue primarily through the research, development, production, and sale of biopharmaceutical products, amounting to CN¥1874.14 million. Its operations encompass the entire lifecycle of antibody drugs from inception to market.

Akeso's recent earnings report shows a significant drop in revenue to ¥1.02 billion from ¥3.68 billion, with a net loss of ¥238.59 million compared to last year's net income of ¥2.53 billion. Despite these figures, the company's R&D expenses highlight its commitment to innovation, particularly in developing ivonescimab for NSCLC treatment, which has shown promising results with a 32.7% increase in efficacy over standard treatments and ongoing trials covering 16 indications globally. Akeso's strategic focus on bi-specific antibodies and robust pipeline positions it well for future growth amid the evolving biotech landscape in Hong Kong.

• Get an in-depth perspective on Akeso's performance by reading our health report here.

• Evaluate Akeso's historical performance by accessing our past performance report.

Next Steps

• Navigate through the entire inventory of 45 SEHK High Growth Tech and AI Stocks here.

• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.

• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SEHK:3888 SEHK:6990 and SEHK:9926.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com